Novartis Kisqali® now first and only CDK4/...
Novartis Kisqali® now first and only CDK4/6 inhibitor indicated in US as first-line therapy specifically for premenopausal women; and as initial therapy with fulvestrant in postmen...
Since 2004, brands have counted on Cision’s MultiVu to create and distribute their important news and marketing content to the world.
Let's talkSearch our recent client collaborations below: